- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01438450
Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma (OTCHCC)
RCT Of Oral Thalidomide And Capecitabine Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma (BCLC D)
연구 개요
상세 설명
Aim The aim of the study is to compare the effect of Oral chemotherapeutic drugs (Thalidomide and Capecitabine) in comparison with supportive therapy in the treatment of advanced Hepatocellular carcinoma in a randomized controlled trial.
Setting The study would be conducted at the All India Institute of Medical Sciences, New Delhi, a tertiary care teaching hospital, in the departments of Gastroenterology and Radiodiagnosis.
Diagnostic criteria
- Cirrhosis of liver- Diagnosis will be founded on the basis of clinical, biochemical, imaging and endoscopy findings.
Hepatocellular carcinoma- when any one of the following is present
- Two imaging modalities (dual phase CT (DPCT)/ contrast enhanced MRI) showing arterialization of the hepatic mass
- AFP more than 400ng/ml along with arterialisation on one imaging modality (DPCT/ contrast enhanced MRI)
- Fine needle aspiration cytology (FNAC)
Definitions
Advanced HCC-(BCLC D) Liver mass (solitary or multiple)with vascular involvement with any of the following
- extrahepatic disease
- distant metastasis
- PST score >2
Barcelona Clinic Liver Cancer (BCLS) staging is based on the BCLC classification (Llovet JM et al. Lancet 2003). Liver cancer is staged into BCLC A- D according to this classification.
Tumor response: Based on DP contrast-enhanced computed tomography (CECT) done every 1, 3, 6 months after starting oral chemotherapy the response will be graded into the following- Complete response (CR): Tumor resolved completely Partial response (PR): Tumor size decreased >50% (product of 2 large diameters) Minor response (MR): Tumor size decreased 25 - 50% Stable disease (SD): Tumor size + 25% No response (NR): No change Disease progression Fresh lesions or recurrence
Patient tolerance Grade 1: no side effects Grade 2: moderate side effects Grade 3: severe side effects Grade 4: life threatening side effects
Performance status (PST score) PST score of 0-4 would be assessed on the following basis 0- No cancer related symptoms. Normal life style
- Minor symptoms related to cancer. Capable of non-strenuous activity.Fully ambulatory and capable of all self-care but unable to carry out any work activities. Confined to bed less than 50% of waking hours
- Capable of only limited self-care. Confined to bed more than 50% of waking hours.
- Completely disabled. Cannot carry on any self-care. Totally confined to bed.
- Dead
Sample Size Earlier studies have shown 1-year response rate of 10% for doxorubicin and 25% response rate for thalidomide. Combining these two drugs, 25% response rate is taken in the oral chemotherapy group, 37 patients are needed in each group. (Total 74 pts)
Randomization
- Patients will be randomized after the confirmation of diagnosis and obtaining written consent
- Sequences will be generated by the Statistician
- Randomization will be done by drawing consecutively numbered opaque sealed envelopes
Follow up Clinical follow up
- All patients would be followed up in the Liver clinic monthly unless their clinical condition warrants earlier follow up
- Liver function tests/ complete blood count would also be done at each visit and Alpha fetoprotein (AFP) (if elevated earlier) every six months
- Patient tolerance, child's status would be estimated.
- Side effects to the drugs would be noted.
Imaging follow up
- At one month, a dual phase CT would be done to ascertain the response to therapy and the need to repeat the procedure. Subsequently, the DPCT would be done at 3 and 6 monthly intervals in the arm receiving oral chemotherapy.
Duration of follow up- one year after starting chemotherapy
연구 유형
등록 (예상)
단계
- 2 단계
- 3단계
연락처 및 위치
연구 장소
-
-
Delhi
-
New Delhi, Delhi, 인도, 110029
- 모병
- All India Institute of Medical Sciences
-
연락하다:
- Subrat K Acharya, DM
- 전화번호: 4934 91-112658500
- 이메일: subratacharya2004@yahoo.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients above 12 years of age with
- ECOG performance status (PST) score of 3 or above
- Underlying Child's A and B cirrhosis
- More than 50% involvement of liver by tumor
- Thrombosed main portal vein
- HV/IVC thrombosis
- Extra hepatic disease
- Metastatic disease
- Informed written consent of patient
Exclusion Criteria:
- History of drug allergy
- Co-morbid illness like coronary artery disease, congestive heart failure, chronic renal failure etc
- Pregnancy
- Outstation patients from distant areas not in a position to follow up
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
간섭 없음: Supportive
Supportive therapy
|
No specific therapy will be given
다른 이름들:
|
활성 비교기: Oral
Oral thalidomide and capecitabine
|
Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained. Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
활착
기간: 일년
|
일년
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
삶의 질
기간: 일년
|
일년
|
|
Tumour response
기간: 1 year
|
1 year
|
|
Number of patients with side effects
기간: 1 year
|
Patients developing various adverse events will be recorded
|
1 year
|
Change from baseline in Child status at 1 year
기간: 1 year
|
Child status is calculated from the following 5 parameters
Child A: score 5-6, Child B: 7-9 and Child C: 10 or more |
1 year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Subrat K Acharya, DM, All India Institute of Medical Sciences, New Delhi
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .